INTERVENTION 1:	Intervention	0
Treatment (Pazopanib Hydrochloride)	Intervention	1
pazopanib hydrochloride	CHEBI:71217	11-34
Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Intervention	2
pazopanib	CHEBI:71219	22-31
disease	DOID:4,OGMS:0000031	104-111
pazopanib hydrochloride: Given orally	Intervention	3
pazopanib hydrochloride	CHEBI:71217	0-23
pharmacological study: Correlative studies	Intervention	4
laboratory biomarker analysis: Correlative studies	Intervention	5
biomarker	CHEBI:59163	11-20
Criteria:	Eligibility	0
No prior bevacizumab	Eligibility	1
Histologically or cytologically confirmed invasive breast carcinoma (recurrent or metastatic disease)	Eligibility	2
breast carcinoma	HP:0003002,DOID:3459	51-67
recurrent	HP:0031796	69-78
disease	DOID:4,OGMS:0000031	93-100
Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques or >= 10 mm by spiral CT scan	Eligibility	3
disease	DOID:4,OGMS:0000031	11-18
ct	BAO:0002125	129-131
Patients who may still benefit from hormonal therapy are ineligible (patients with hormone receptor-positive breast cancer should have received appropriate sequential hormonal therapy for metastatic disease until disease progression)	Eligibility	4
hormone	CHEBI:24621	83-90
breast cancer	DOID:1612	109-122
disease	DOID:4,OGMS:0000031	199-206
disease	DOID:4,OGMS:0000031	213-220
Patients with HER-2 positive disease who have not yet received trastuzumab (Herceptin®) to maximal benefit are ineligible (patients with disease progression during trastuzumab therapy are eligible)	Eligibility	5
disease	DOID:4,OGMS:0000031	29-36
disease	DOID:4,OGMS:0000031	137-144
No known brain metastases	Eligibility	6
brain	UBERON:0000955	9-14
ECOG performance status (PS) 0-1 or Karnofsky PS 60-100%	Eligibility	7
Life expectancy > 12 weeks	Eligibility	8
Absolute neutrophil count >= 1,500/mm³	Eligibility	9
Platelets >=100,000/mm³	Eligibility	10
Total bilirubin normal (exception made for patients with known Gilbert's disease)	Eligibility	11
disease	DOID:4,OGMS:0000031	73-80
AST/ALT =< 2.5 times upper limit of normal (ULN)	Eligibility	12
No proteinuria > +1 on two consecutive dipsticks taken >= 1 week apart	Eligibility	13
proteinuria	HP:0000093,DOID:576	3-14
week	UO:0000034	60-64
PT/INR/PTT =< 1.2 times ULN	Eligibility	14
No allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other study agents	Eligibility	15
pazopanib	CHEBI:71219	93-102
No QTc prolongation (defined as a QTc interval >= 500 msecs) or other significant ECG abnormalities	Eligibility	16
qtc interval	CMO:0000269	34-46
No condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, or active peptic ulcer disease) that would impair ability to swallow and retain study drug	Eligibility	17
condition	PDRO:0000129	3-12
disease	DOID:4,OGMS:0000031	43-50
disease	DOID:4,OGMS:0000031	162-169
active peptic ulcer disease	DOID:749	142-169
drug	CHEBI:23888	225-229
No poorly controlled hypertension (systolic blood pressure [BP] >= 140 mm Hg or diastolic BP >= 90 mm Hg) Initiation or adjustment of BP medication is allowed prior to study entry provided that the average of 3 BP readings prior to study entry is < 140/90 mm Hg	Eligibility	18
hypertension	HP:0000822,DOID:10763	21-33
systolic blood pressure	CMO:0000004	35-58
No serious or non-healing wound, ulcer, or bone fracture	Eligibility	19
ulcer	OAE:0004372	33-38
bone fracture	HP:0020110	43-56
No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the last 4 weeks	Eligibility	20
abscess	HP:0025615	71-78
No cerebrovascular accident within the last 6 months	Eligibility	21
No myocardial infarction, cardiac arrhythmia, hospital admission for unstable angina within the last 12 weeks	Eligibility	22
myocardial infarction	HP:0001658,DOID:5844	3-24
arrhythmia	HP:0011675	34-44
No venous thrombosis within the last 12 weeks	Eligibility	23
venous thrombosis	HP:0004936	3-20
No NYHA class III-IV heart failure Patients with a history of class II heart failure may be considered eligible provided they are asymptomatic on treatment	Eligibility	24
heart	UBERON:0000948	21-26
heart	UBERON:0000948	71-76
history	BFO:0000182	51-58
No concurrent uncontrolled illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would preclude study compliance	Eligibility	25
active	PATO:0002354	77-83
Not pregnant or nursing	Eligibility	26
Negative pregnancy test	Eligibility	27
Fertile patients must use effective contraception	Eligibility	28
At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, or surgery	Eligibility	29
mitomycin c	CHEBI:27504	71-82
radiotherapy	OAE:0000235	85-97
surgery	OAE:0000067	102-109
No cardiac angioplasty or stenting within the last 12 weeks	Eligibility	30
No more than 1 prior chemotherapy regimen for recurrent disease	Eligibility	31
recurrent	HP:0031796	46-55
disease	DOID:4,OGMS:0000031	56-63
No prior surgical procedures affecting absorption	Eligibility	32
No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:	Eligibility	33
Therapeutic warfarin Low molecular weight heparin or prophylactic low-dose warfarin are allowed	Eligibility	34
warfarin	CHEBI:10033	12-20
warfarin	CHEBI:10033	75-83
heparin	CHEBI:28304	42-49
No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:	Eligibility	35
Erectile dysfunction agents: sildenafil, tadalafil, or vardenafil	Eligibility	36
erectile dysfunction	HP:0100639,DOID:1875	0-20
sildenafil	CHEBI:9139	29-39
tadalafil	CHEBI:71940	41-50
vardenafil	CHEBI:46295	55-65
Antiarrhythmics: bepridil, flecainide, lidocaine, mexilitine, amiodarone, or quinidine	Eligibility	37
bepridil	CHEBI:3061	17-25
flecainide	CHEBI:75984	27-37
lidocaine	CHEBI:6456	39-48
amiodarone	CHEBI:2663	62-72
quinidine	CHEBI:28593,BAO:0000797	77-86
Immune modulators: cyclosporine, tacrolimus, or sirolimus	Eligibility	38
sirolimus	CHEBI:9168	48-57
Miscellaneous: theophylline, quetiapine, or risperidone	Eligibility	39
theophylline	CHEBI:28177	15-27
quetiapine	CHEBI:8707	29-39
risperidone	CHEBI:8871	44-55
No CYP2C9 substrates during or for 1-2 weeks after completion of study treatment, including any of the following:	Eligibility	40
Oral hypoglycemics: glipizide, glyburide, or tolbutamide	Eligibility	41
glipizide	CHEBI:5384	20-29
glyburide	CHEBI:5441	31-40
tolbutamide	CHEBI:27999	45-56
Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, or methylergonovine	Eligibility	42
dihydroergotamine	CHEBI:4562	19-36
ergotamine	CHEBI:64318	26-36
ergotamine	CHEBI:64318	50-60
Neuroleptics: pimozide	Eligibility	43
pimozide	CHEBI:8212	14-22
No concurrent combination antiretroviral therapy for HIV-positive patients	Eligibility	44
No other concurrent investigational agents	Eligibility	45
No other concurrent anticancer therapy	Eligibility	46
WBC >= 3,000/mm³	Eligibility	47
No more than 2 prior palliative systemic chemotherapy regimens for de novo metastatic disease	Eligibility	48
disease	DOID:4,OGMS:0000031	86-93
Creatinine normal OR creatinine clearance >= 60 mL/min	Eligibility	49
creatinine	CHEBI:16737	0-10
creatinine	CHEBI:16737	21-31
creatinine clearance	CMO:0000765	21-41
At least 3 months since prior trastuzumab	Eligibility	50
Outcome Measurement:	Results	0
Number of Participants With Partial and Complete Response.	Results	1
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT / MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR	Results	2
target	BAO:0003064	76-82
target	BAO:0003064	162-168
target	BAO:0003064	254-260
ct	BAO:0002125	107-109
diameter	PATO:0001334	242-250
Time frame: Up to 3 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Treatment (Pazopanib Hydrochloride)	Results	5
pazopanib hydrochloride	CHEBI:71217	28-51
Arm/Group Description: Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Results	6
pazopanib	CHEBI:71219	45-54
disease	DOID:4,OGMS:0000031	127-134
pazopanib hydrochloride: Given orally	Results	7
pazopanib hydrochloride	CHEBI:71217	0-23
pharmacological study: Correlative studies	Results	8
laboratory biomarker analysis: Correlative studies	Results	9
biomarker	CHEBI:59163	11-20
Overall Number of Participants Analyzed: 21	Results	10
Measure Type: Number	Results	11
Unit of Measure: participant  1	Results	12
Adverse Events 1:	Adverse Events	0
Total: 1/21 (4.76%)	Adverse Events	1
Intra abdominal hemorrhage  1/21 (4.76%)	Adverse Events	2
Esophagitis  1/21 (4.76%)	Adverse Events	3
esophagitis	HP:0100633,DOID:11963	0-11
